KPTI

Karyopharm Therapeutics Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.02

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %224.1 / %30

Non-compliant assets / Total market cap %9.1 / %30

Non-compliant revenue / Total income %1.8 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

Website

Analysis (Turkish): KPTI Hissesi Caiz mi, Helal mi? Karyopharm Therapeutics Inc. Katılım Analizi